eng Science and Education Publishing American Journal of Medical Case Reports 2374-216X 2022-10-24 10 10 271 273 10.12691/ajmcr-10-10-5 AJMCR202210105 article In¨ºs Barbosa 1 Ezequiel Pinto epinto@ualg.pt 2 3 Maria Gra?a Sequeira Munoz 4 Tania Nascimento 4 4 Sandra Pais 4 4 5 Faculty of Medicine and Biomedical Sciences, University of Algarve, Faro, Portugal University of Algarve, School of Health, Faro, Portugal Centro Hospitalar Universit¨¢rio do Algarve, Faro, Portugal This short case-series reports a 6-month follow up of 5 rheumatoid arthritis patients (2 males, 3 females) 60 years-old or above, with Tocilizumab treatment which was discontinued due to stock off in July 2021. Patients switched treatment to other DMARD (Upadacitinib, Baricitinib, or Certolizumab pegol). We report clinical data and the Disease Activity Score for Rheumatoid Arthritis. Upadacitinib, Baricitinib, and Certolizumab appear therapeutically equivalent to Tocilizumab in a 6-month follow-up. http://pubs.sciepub.com/ajmcr/10/10/5/ajmcr-10-10-5.pdf Tocilizumab rheumatoid arthritis